-
-
SPEVIGO
- QTY 7.5
- 450 MG/7.5
- VIAL
- Near 77381
SPESOLIMAB (spe SOE li mab) treats psoriasis. It works by slowing down an overactive immune system. This reduces itching and inflammation. It is a monoclonal antibody.
Change Location
Set Price Drop Alert for:
SPEVIGO
- QTY 7.5
- 450 MG/7.5
- VIAL
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
SPEVIGO
- QTY 7.5
- 450 MG/7.5
- VIAL
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Change Form
Medicine Chest
SPEVIGO Lifestyle Interactions
-
Doxazosin Mesylate 4mg, Oral tablet
• Interaction: Alcohol• Severity: Major• Notes for Consumers: Do not drink alcohol while taking this medication. Drinking alcohol while taking this medication increases the risk for dangerously low blood pressure. Contact your care team right away if you experience dizziness, feeling faint or lightheaded, or blurry vision.• Notes for Professionals: Advise patients to avoid alcohol consumption while taking alpha-blockers. Concomitant use may increase the risk for hypotension. -
Doxazosin Mesylate 4mg, Oral tablet
• Interaction: Grapefruit juice• Severity: Moderate• Notes for Consumers: Although an interaction is possible, these drugs may be used together. Side effects of Doxazosin may get worse. If the blood pressure drops too low while taking these medications, you may become dizzy or feel faint. To limit this interaction, do not stand or sit up too quickly. Contact your prescriber if you have dizziness which does not go away.• Notes for Professionals: Monitor blood pressure and for signs of hypotension during coadministration. The plasma concentrations of doxazosin may be elevated when administered concurrently with grapefruit juice. Grapefruit juice is a strong CYP3A4 inhibitor; doxazosin is a CYP3A4 substrate. Coadministration of doxazosin with a moderate CYP3A4 inhibitor resulted in a 10% increase in mean AUC and an insignificant increase in mean Cmax and mean half-life of doxazosin. Although not studied in combination with doxazosin, strong CYP3A4 inhibitors may have a larger impact on doxazosin concentrations and therefore should be used with caution.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
